Adalimumab

Generic Name: Adalimumab

Brand Names: Amjevita, Cyltezo, Humira, Hyrimoz, Yusimry, Hulio, Hefiya, Libmyris, Imraldi, Amsparity, Idacio, Hukyndra, Amgevita, Yuflyma

Drug Type: Biotech

Chemical Formula: -

CAS Number: 331731-18-1

Unique Ingredient Identifier: FYS6T7F842

Background: Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced by recombinant DNA technology usi...

Indication: Adalimumab is indicated for the following conditions:

Adalimumab has also been used off-label to treat Pyoderma gangrenosum.

Associated Conditions: Ankylosing Spondylitis (AS), Hidradenitis Suppurativa (HS), Moderate to Severe Chronic Plaque Psoriasis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Crohn's Disease, Moderately to Severely Active Ulcerative Colitis, Non-infectious Intermediate, Posterior and Panuveitis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Pyoderma Gangrenosum

Associated Therapies: -

Clinical Trials

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Not Applicable

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: adalimumab

First Posted Date: 2007-07-06

Last Posted Date: 2008-12-05

Lead Sponsor: University Hospital, Tours

Target Recruit Count: 8

Registration Number: NCT00497614

Locations: 🇫🇷
University Hospital of Tours, Tours, France

Danish Multicenter Study of Adalimumab in Spondyloarthritis

Phase 4

Conditions: Spondyloarthritis

Interventions: Drug: Placebo
Drug: Adalimumab

First Posted Date: 2007-05-24

Last Posted Date: 2012-03-28

Lead Sponsor: Glostrup University Hospital, Copenhagen

Target Recruit Count: 52

Registration Number: NCT00477893

Locations: 🇩🇰
Department of Rheumatology, Vejle Hospital, Vejle, Denmark
🇩🇰
Department of Radiology, Aabenraa Hospital, Aabenraa, Denmark
🇩🇰
Department of Radiology, Herlev University Hospital, Copenhagen, Denmark

and more 10 locations

Adalimumab in Severe and Acute Sciatica

Phase 2

Completed

Conditions: Sciatica

Interventions: Drug: Placebos
Drug: Adalimumab

First Posted Date: 2007-05-07

Last Posted Date: 2019-04-22

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 61

Registration Number: NCT00470509

Locations: 🇨🇭
Geneva University Hospital, Geneva, Switzerland

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

Phase 3

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2007-01-29

Last Posted Date: 2008-05-02

Lead Sponsor: Abbott

Target Recruit Count: 127

Registration Number: NCT00427362

Open-Label Adalimumab for Ulcerative Colitis Patients

Phase 1

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2007-01-12

Last Posted Date: 2012-08-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 20

Registration Number: NCT00421642

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

Phase 2

Conditions: Uveitis

Interventions: Drug: Adalimumab

First Posted Date: 2006-07-04

Last Posted Date: 2012-12-03

Lead Sponsor: Heidelberg University

Target Recruit Count: 40

Registration Number: NCT00348153

Locations: 🇩🇪
Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany

Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)

Phase 3

Completed

Conditions: Crohn's Disease

First Posted Date: 2006-06-20

Last Posted Date: 2007-11-29

Lead Sponsor: Abbott

Target Recruit Count: 1000

Registration Number: NCT00338650

Trial of Adalimumab in Progressive Sarcoidosis

Phase 2

Terminated

Conditions: Sarcoidosis

Interventions: Drug: Adalimumab

First Posted Date: 2006-04-05

Last Posted Date: 2020-08-25

Lead Sponsor: University of Chicago

Target Recruit Count: 11

Registration Number: NCT00311246

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Phase 3

Completed

Conditions: Giant Cell Arteritis

Interventions: Drug: adalimumab
Drug: placebo

First Posted Date: 2006-03-22

Last Posted Date: 2012-07-10

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 69

Registration Number: NCT00305539

Locations: 🇫🇷
Hôpital Bicêtre, Kremlin Bicêtre, France

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Phase 2

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: IDEC-C2B8 (rituximab)
Drug: Placebo
Drug: Methotrexate
Drug: Etanercept
Drug: Adalimumab
Drug: Methylprednisolone
Dietary Supplement: Folate

First Posted Date: 2006-03-02

Last Posted Date: 2015-09-28

Lead Sponsor: Biogen

Target Recruit Count: 54

Registration Number: NCT00298272

Locations: 🇺🇸
Research Site, Burlington, Vermont, United States
🇺🇸
Research site, Chardon, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy